Drug-Eluting Balloon Catheters Market by Product Type (Bare Balloon Catheters, Drug-Eluting Balloon Catheters), by End-Use Industry (Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Laboratories), by Application (Coronary Artery Disease Treatment, Peripheral Artery Disease Treatment); Global Trends and Forecast (2024 – 2030)

As per Intent Market Research, the Drug-Eluting Balloon Catheters Market was valued at USD 2.3 billion in 2023 and will surpass USD 6.7 billion by 2030; growing at a CAGR of 16.4% during 2024 - 2030.

The drug-eluting balloon catheters market is experiencing rapid growth due to the increasing prevalence of vascular diseases, particularly coronary artery disease (CAD) and peripheral artery disease (PAD). Drug-eluting balloon (DEB) catheters combine the mechanical advantage of balloon angioplasty with the therapeutic benefit of drug delivery. These catheters are used to treat narrowed or blocked arteries by delivering drugs directly to the site of stenosis, reducing the risk of restenosis and improving long-term outcomes for patients. The demand for DEB catheters is further driven by the need for minimally invasive treatments, advancements in catheter technology, and the growing preference for effective alternatives to traditional surgical interventions.

The global market for drug-eluting balloon catheters is set to expand as healthcare providers focus on providing advanced solutions to manage cardiovascular diseases and peripheral vascular diseases. This market is also supported by ongoing research into drug formulations and new catheter designs that enhance the delivery of therapeutic agents.

Drug-Eluting Balloon Catheters Segment is Largest Owing to Improved Efficacy and Safety

Within the product types, drug-eluting balloon catheters hold the largest market share. These catheters combine the angioplasty balloon with an anti-proliferative drug that is delivered directly to the vascular wall during the procedure. This results in a significant reduction in the risk of restenosis compared to bare balloon catheters, making DEBs particularly effective for treating complex coronary and peripheral artery disease. The use of these catheters has been shown to improve patient outcomes, reduce the need for repeat procedures, and offer a safer alternative to bare metal stents.

The effectiveness of drug-eluting balloon catheters in reducing the long-term risk of restenosis, especially in high-risk patients, has driven their widespread adoption. As a result, the drug-eluting balloon catheter segment is expected to continue to dominate the market, with ongoing technological innovations and improvements in drug formulations further enhancing their clinical efficacy.

Coronary Artery Disease Treatment Segment is Largest Due to High Prevalence

The coronary artery disease (CAD) treatment segment is the largest application area for drug-eluting balloon catheters. CAD, which involves the narrowing of the coronary arteries due to plaque buildup, is one of the leading causes of heart attacks and a major contributor to cardiovascular morbidity worldwide. The growing prevalence of CAD, particularly among aging populations and individuals with risk factors such as diabetes, hypertension, and smoking, has led to an increased demand for effective treatment solutions like drug-eluting balloon catheters.

Drug-eluting balloons are preferred for treating CAD due to their ability to provide localized drug delivery to the site of stenosis, reducing the likelihood of restenosis and the need for repeat revascularization procedures. As cardiovascular diseases remain a leading cause of death globally, the CAD treatment segment will continue to be a key driver of market growth in the drug-eluting balloon catheter industry.

Hospitals Segment is Largest End-Use Industry Due to High Procedure Volume

Among the end-use industries, hospitals account for the largest share of the market. Hospitals are the primary setting for vascular procedures, including angioplasty and stenting, and have a higher volume of patients requiring treatment for coronary artery disease and peripheral artery disease. With the growing adoption of minimally invasive procedures and the availability of advanced medical devices like drug-eluting balloon catheters, hospitals are increasingly turning to these devices to improve patient outcomes.

Moreover, hospitals benefit from a broader range of resources, including specialized medical professionals and advanced imaging equipment, which enable the successful use of drug-eluting balloon catheters in complex procedures. As a result, the hospital segment is expected to maintain its dominance in the drug-eluting balloon catheter market.

North America Leads the Market Due to Advanced Healthcare Infrastructure

North America holds the largest market share in the drug-eluting balloon catheters market, driven by the region's advanced healthcare infrastructure, high adoption rates of innovative medical devices, and the presence of major healthcare players. The United States, in particular, accounts for a significant portion of the market due to the high prevalence of coronary artery disease and peripheral artery disease among its aging population.

In addition, the region benefits from well-established reimbursement policies, which make drug-eluting balloon catheters more accessible to healthcare providers and patients. North America’s strong regulatory environment and focus on healthcare innovations further contribute to its dominance in the market. The region is expected to continue leading the market, with increasing demand for minimally invasive cardiovascular treatments and ongoing technological advancements in drug-eluting balloon catheter design.

Competitive Landscape and Key Players

The drug-eluting balloon catheters market is competitive, with a number of key players driving innovation and expansion. Leading companies in the market include Medtronic, Boston Scientific, Abbott Laboratories, Terumo Corporation, and B. Braun Melsungen AG. These companies are investing heavily in research and development to enhance the functionality and effectiveness of drug-eluting balloon catheters, particularly by improving drug formulations and balloon designs.

The competitive landscape also features strategic partnerships, mergers, and acquisitions as companies seek to expand their product portfolios and geographic reach. Additionally, companies are increasingly focusing on clinical studies and regulatory approvals to demonstrate the long-term benefits and safety of drug-eluting balloon catheters. As the market continues to grow, competition is expected to intensify, with both established players and new entrants striving to capture market share through innovation and product differentiation.

Recent Developments:

• Medtronic PLC launched a new generation of drug-eluting balloon catheters, improving performance and efficacy in coronary artery disease treatment.
• Boston Scientific Corporation received FDA approval for its latest drug-eluting balloon catheter, designed for complex coronary interventions.
• Abbott Laboratories introduced a hybrid balloon catheter that combines drug-eluting technology with enhanced delivery mechanisms for treating peripheral artery disease.
• Terumo Corporation announced a strategic partnership with a leading medical research organization to develop next-generation drug-eluting balloon catheters.
• Cordis expanded its drug-eluting balloon catheter portfolio with the addition of a device focused on treating challenging vascular lesions in peripheral arteries.

List of Leading Companies:

• Boston Scientific Corporation
• Medtronic PLC
• Abbott Laboratories
• Terumo Corporation
• Cordis (a Cardinal Health Company)
• Cook Medical
• Johnson & Johnson (Ethicon)
• B. Braun Melsungen AG
• Cardiovascular Systems, Inc.
• Asahi Intecc Co., Ltd.
• Strata Medical
• Spectranetics (acquired by Philips)
• MicroPort Scientific Corporation
• Osaka Medical Co., Ltd.
• EndoSpan Ltd.

Report Scope: